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SARS-CoV-2, the virus responsible for COVID-19, has caused a global pandemic. Antibodies
can be powerful biotherapeutics to fight viral infections. Here, we use the human apoferritin
protomer as a modular subunit to drive oligomerization of antibody fragments and transform
antibodies targeting SARS-CoV-2 into exceptionally potent neutralizers. Using this platform,
half-maximal inhibitory concentration (IC50) values as low as 9 × 10−14 M are achieved as a
result of up to 10,000-fold potency enhancements compared to corresponding IgGs. Com-
bination of three different antibody specificities and the fragment crystallizable (Fc) domain
on a single multivalent molecule conferred the ability to overcome viral sequence variability
together with outstanding potency and IgG-like bioavailability. The MULTi-specific, multi-
Affinity antiBODY (Multabody or MB) platform thus uniquely leverages binding avidity
together with multi-specificity to deliver ultrapotent and broad neutralizers against SARS-
CoV-2. The modularity of the platform also makes it relevant for rapid evaluation against
other infectious diseases of global health importance. Neutralizing antibodies are a promising
therapeutic for SARS-CoV-2.
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The continuous threat to public health from respiratoryviruses such as the novel SARS-CoV-2 underscores theurgent need to rapidly develop and deploy prophylactic
and therapeutic interventions to combat pandemics. Monoclonal
antibodies (mAbs) have been used effectively for the treatment of
infectious diseases as exemplified by palivizumab for the pre-
vention of respiratory syncytial virus in high-risk infants1 or
Zmapp, mAb114, and REGN-EB3 for the treatment of Ebola2.
Consequently, mAbs targeting the Spike (S) protein of SARS-
CoV-2 have been a focus for the development of biomedical
countermeasures against COVID-19. To date, several antibodies
targeting the S protein have been identified3–19 with bamlanivi-
mab being the first antibody approved in the United States by the
Food and Drug Administration (FDA) for the emergency treat-
ment of SARS-CoV-2 in November 2020. Receptor binding
domain (RBD)-directed mAbs that interfere with binding to
angiotensin converting enzyme 2 (ACE2), the receptor for cell
entry20, are usually associated with the highest neutralization
potencies6,18,19.
mAbs can be isolated by B-cell sorting from infected donors,
immunized animals, or by identifying binders in preassembled
libraries. Despite these methodologies being robust and reliable for
the discovery of virus-specific mAbs, identification of the best anti-
body clone is usually associated with a time-cost penalty. In addition,
RNA viruses have higher mutations rates than DNA viruses and such
mutations can significantly alter the potency of neutralizing anti-
bodies. Indeed, several studies have already shown a reduction in
neutralization potency from convalescent serum and resistance of
certain mAbs21–23 to the more recent B.1.1.724, B.1.35125, and
B.1.1.2826,27 variants of SARS-CoV-2. Hence, there is an unmet need
for the development of a platform that bridges antibody discovery
and the rapid identification and deployment of highly potent neu-
tralizers less susceptible to viral sequence variability.
The potency of an antibody is greatly affected by its ability to
simultaneously interact multiple times with its epitope28–30. This
enhanced apparent affinity, known as avidity, has been previously
reported to increase the neutralization potency of nanobodies31,32
and of IgGs over Fabs8,10,16 against SARS-CoV-2. To leverage the
full power of binding avidity, we have developed an antibody-
scaffold technology using the human apoferritin protomer as a
modular subunit to multimerize antibody fragments and propel
mAbs into ultrapotent neutralizers against SARS-CoV-2. Indeed,
the resulting Multabody molecules can increase potency by up to
four orders of magnitude over corresponding IgGs. In addition,
we demonstrate the ability of this technology to combine three
different Fab specificities to better overcome point mutations in
the Spike. The Multabody offers a versatile IgG-like “plug-and-
play” platform to enhance antiviral characteristics of mAbs
against SARS-CoV-2, and demonstrates the power of avidity as a
mechanism to be leveraged against viral pathogens.
Results
Avidity enhances neutralization potency. We used the self-
assembly of the light chain of human apoferritin to multimerize
antigen binding moieties targeting the SARS-CoV-2 S glycopro-
tein. Apoferritin protomers self-assemble into an octahedrally
symmetric structure with an ~6 nm hydrodynamic radius (Rh)
composed of 24 identical polypeptides33. The N terminus of each
apoferritin subunit points outwards of the spherical nanocage and
is therefore accessible for the genetic fusion of proteins of interest.
Upon folding, apoferritin protomers act as building blocks that
drive the multimerization of the 24 proteins fused to their N
termini (Fig. 1a).
First, we investigated the impact of multivalency on the ability
of the single chain variable domain VHH-72 to block viral
infection. VHH-72 has been previously described to neutralize
SARS-CoV-2 when fused to a Fc domain, but not in its
monovalent format31. The light chain of human apoferritin
displaying 24 copies of VHH-72 assembled into monodisperse,
well-formed spherical particles (Fig. 1b, c) and showed an
enhanced binding avidity to the S glycoprotein (Fig. 1d) in
comparison to bivalent VHH-72-Fc. Strikingly, display of VHH-
72 on the light chain of human apoferritin achieved a ~10,000-
fold increase in neutralization potency against SARS-CoV-2
pseudovirus (PsV) compared to the conventional Fc fusion
(Fig. 1e), demonstrating the power of avidity to transform
binding moieties into potent neutralizers.
Multabodies have IgG-like properties. The Fc confers IgGs
in vivo half-life and effector functions through interaction with
neonatal Fc receptor (FcRn) and Fc gamma receptors (FcγR),
respectively. To confer these IgG-like properties to our multimeric
scaffold, we next sought to incorporate both binding moieties and
Fc domains. Because a Fab is a hetero-dimer consisting of a light
and a heavy chain, and the Fc is a homodimer, we created single-
chain Fab (scFab) and single-chain Fc (scFc) polypeptide con-
structs. scFab and scFc domains were directly fused to the N
terminus of the apoferritin protomer. For in vivo proof-of-
principle experiments, we generated a species-matched surrogate
molecule that consists of mouse light chain apoferritin fusions to a
mouse scFab and a mouse scFc (IgG2a subtype). Binding kinetics
showed that the resulting MB molecule binds mouse FcRn in a pH
dependent manner—binding at endosomal pH (5.6) and no
binding at physiological pH (7.4)—similar to the parental IgG
(Fig. 2a). Expectedly, binding to the high-affinity mouse FcγR1
was enhanced through avidity effects in comparison to the par-
ental IgG. Hence, we generated a modified mouse scFc version
that includes the FcγR-silencing mutations LALAP to lower Fc
binding in a multimeric context (Fig. 2a). Subcutaneous admin-
istration of MBs in C57BL/6 or BALB/c mice was well tolerated
with no decrease in body weight or visible adverse events. The MB
showed favorable IgG-like serum half-life (Fig. 2b), with a pro-
longed detectable titer in the sera for the lower FcγR-binding MB
(LALAP Fc sequence) compared to the WT MB, indicative of a
role for the Fc in dictating in vivo bioavailability. Live 2D and 3D-
imaging revealed that the fluorescently-labeled MB biodistributed
systemically like the corresponding IgG, without accumulation in
any specific tissue (Fig. 2c and Fig. S1). In contrast, 15 nm gold
nanoparticles (GNP), which have a similar Rh as MBs, rapidly
disseminated from the site of injection (Fig. 2c and Fig. S1).
Presumably because all sequences derived from the host, the
surrogate mouse MB did not induce an anti-drug antibody
response in mice (Fig. 2d), thus further highlighting the IgG-like
properties of the MB platform.
Protein engineering to achieve higher valency. In view of these
favorable results for a mouse MB surrogate, we aimed to generate
fully-human MBs derived from the previously reported IgG
BD2312 and IgG 4A813 that target the SARS-CoV-2 spike RBD
and N-terminal domain (NTD), respectively. Addition of scFcs
into the MB reduces the number of scFabs that can be multi-
merized. In order to endow the MB platform with Fc without
compromising Fab avidity and hence neutralization potency, we
engineered the apoferritin protomer to accommodate more than
24 components per particle. Based on its four-helical bundle fold,
the human apoferritin protomer was split into two halves: the two
N-terminal α helices (N-Ferritin) and the two C-terminal α
helices (C-Ferritin). In this configuration, the scFc fragment of
human IgG1 and the scFab of anti-SARS-CoV-2 IgGs were
genetically fused at the N terminus of each apoferritin half,
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respectively. Split apoferritin complementation led to hetero-
dimerization of the two halves and consequently resulted in a
very efficient hetero-dimerization process of the fused proteins.
Co-expression of the scFab-C-Ferritin and scFc-N-Ferritin genes
together with the scFab-Ferritin gene in excess resulted in a full
apoferritin self-assembly that displays high numbers of scFab and
low numbers of scFc on the nanocage periphery (Fig. 3a and
Materials and Methods). Conveniently, this design allows for the
straightforward purification of the MB using Protein A akin to
IgG purification.
This split MB design forms 16 nm Rh spherical particles with
an uninterrupted ring of density and regularly spaced protruding
scFabs and scFc (Fig. 3b, c). Hence, the MB is on the lower size
range of natural IgMs34, but packs more weight on a similar size
to achieve high multi-valency. Binding kinetics experiments
demonstrated that high binding avidity of the MB for the Spike
was preserved upon addition of Fc fragments (Fig. 3d). Binding to
human FcγRI and FcRn at endosomal pH confirmed that scFc
was properly folded in the split MB design. In addition, the
LALAP mutations in the scFc lowered the binding affinity to
human FcγRI (Fig. 3e), as previously observed with the surrogate
mouse MB (Fig. 2a). SARS-CoV-2 PsV neutralization assays with
the split design MBs showed that enhanced binding affinity for
the Spike translates into an improved neutralization potency in
comparison to their IgG counterparts, with a ~1600-fold and
>2000-fold increase for BD23 and 4A8, respectively (Fig. 3f).
Combined, this data supported the further exploration of the MB
as an IgG-like platform that confers exquisite binding avidity and
PsV neutralization across epitopes on different Spike domains.
From antibody discovery to ultrapotent neutralizers. We next
assessed the ability of the MB platform to transform mAb binders
identified from initial phage display screens into potent neu-
tralizers against SARS-CoV-2 (Fig. 4a). Following standard bio-
panning protocols against the RBD of SARS-CoV-2, 20 human
mAb binders with moderate affinities that range from 10-6 to 10-
8 M were selected (Supplementary Data 1). These mAbs were
produced as full-length IgGs and MBs and their capacity to block
viral infection was compared in a neutralization assay against
SARS-CoV-2 PsV (Fig. 4b and Fig. S2a). Notably, MB expression
yields, homogeneity and thermostability was similar to those of
the parental IgG (Fig. S3) and the MB enhanced the potency of 18
out of 20 (90%) IgGs by up to four orders of magnitude. The
largest increment was observed for mAb 298 which went from
a mean IC50 of ~0.3 µg/mL as an IgG to 0.0001 µg/mL as a MB.
Strikingly, 11 mAbs were converted from non-neutralizing IgGs
to neutralizing MBs in the tested concentration ranges. Seven
Fig. 1 Avidity enhances binding and neutralization of VHH against SARS-CoV-2. a Schematic representation of a monomeric VHH domain and its
multimerization using a conventional Fc (dark red) scaffold or human apoferritin (gray). b Size exclusion chromatography and SDS-PAGE of apoferritin
alone (gray) and VHH-72 apoferritin particles (gold). c Negative stain electron microscopy of VHH-72 apoferritin particles. (Scale bar 50 nm,
representative of two independent experiments). d Comparison of the binding avidity (apparent KD) of VHH-72 to SARS-CoV-2 S protein when displayed
in a bivalent (dark red) or 24-mer (gold) format. Bars indicate the mean values of n= 2 biologically independent experiments. Apparent KD lower than 10
−12 M (dash line) is beyond the instrument detection limit. e Neutralization potency against SARS-CoV-2 PsV (color coding is as in (d)). One
representative out of two biologically independent replicates with similar results is shown. Mean values ± SD of two technical replicates is represented in
the plot. Median IC50 values of the two biologically independent replicates are shown. Source data are provided as a Source Data file.
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MBs displayed exceptional potency with IC50 values between
0.2–2 ng/mL against SARS-CoV-2 PsV using two different target
cells (293T-ACE2 and HeLa-ACE2 cells; Fig. 4b and Fig. S2b).
PsV neutralization assays using recombinant mAbs REGN10933
and REGN10987 as benchmark showed similar IC50 values
(0.0044 and 0.030 µg/mL, respectively) to those previously
reported8, and thus confirmed the extraordinary potency of the
MBs observed in our assays. The enhanced neutralization potency
of the MB was further confirmed with authentic SARS-CoV-2
virus for the mAbs with the highest potency (Fig. 4c and Fig. S2c),
as also benchmarked with the two recombinant REGN mAbs.
The less sensitive neutralization phenotype we observed against
authentic virus in comparison to PsV is also in agreement with
previous reports5,6,9,12.
Retrospectively, all IgGs and MBs were tested for their ability
to bind to the Spike glycoprotein and the RBD of SARS-CoV-2
(Fig. S4). Increased avidity resulted in higher apparent binding
affinities with no detectable off-rates against the Spike glycopro-
tein, most likely due to inter-spike crosslinking that translates
into high neutralization potency (Fig. 4b–d and Fig. S4). Overall,
the data show that the MB platform is compatible with rapid
delivery of ultrapotent IgG-like molecules even when starting
with mAbs of modest neutralization characteristics.
Epitope mapping. Based on their neutralization potency, seven
mAbs were selected for further characterization: 298 (IGHV1-46/
IGKV4-1), 82 (IGHV1-46/IGKV1-39), 46 (IGHV3-23/IGKV1-
39), 324 (IGHV1-69/IGKV1-39), 236 (IGHV1-69/IGKV2-28), 52
(IGHV1-69/IGKV1-39), and 80 (IGHV1-69/IGKV4-1) (Fig. 4b
and Supplementary Data 1). Epitope binning experiments showed
that these mAbs target two main sites on the RBD, with one of
these bins overlapping with the ACE2 binding site (Fig. 5a and
Fig. S5). Cryo-EM structures of Fab-SARS-CoV-2 S complexes at
a global resolution of ~6–7 Å confirmed that mAbs 324, 298, and
80 bind overlapping epitopes (Fig. 5b, Fig. S6a–c, and Table S1).
To gain insight into the binding of mAbs targeting the other bin,
we obtained the cryo-EM structure of Fab 46 in complex with the
RBD at a global resolution of 4.0 Å (Fig. 5c, Fig. S6d, and
Table S1), and the crystal structure of Fabs 298 and 52 as a
ternary complex with the RBD at 2.95 Å resolution (Fig. 5d, Fig.
S7, and Table S2).
The crystal structure shows that Fab 298 binds almost
exclusively to the ACE2 receptor binding motif (RBM) of the
RBD (residues 438–506). In fact, out of 16 RBD residues involved
in binding Fab 298, 12 are also involved in ACE2-RBD binding
(Fig. S7a–c and Table S3). The RBM is stabilized by 11 hydrogen
bonds from heavy and light chain residues of Fab 298. In
addition, RBM Phe486 is contacted by 11 Fab 298 residues
Fig. 2 Bioavailability, biodistribution, and immunogenicity of a mouse surrogate Multabody. a Binding kinetics of WT and Fc-modified (LALAP mutation)
MB to mouse FcγRI (left) and mouse FcRn at endosomal (middle) and physiological (right) pH in comparison to the parental IgG. Two-fold dilution series
from 100 to 3 nM (IgG) and 10 to 0.3 nM (MB) were used. Red lines represent raw data; black lines represent global fits. b Five male C57BL/6 mice per
group were used to assess the serum concentration of a surrogate mouse MB, a Fc-modified MB (LALAP mutation), and parental mouse IgGs (IgG1 and
IgG2a subtypes) after subcutaneous administration of 5 mg/kg. c MB and IgG2a samples were labeled with Alexa-647 for visualization of their
biodistribution post subcutaneous injection into three male BALB/c mice/group via live noninvasive 2D whole body imaging. 15 nm fluorescently-labeled
gold nanoparticles (GNP), which have a similar Rh value as the Multabody are shown as a comparator. d Five male C57BL/6 mice per group were used to
assess any anti-drug-antibody response induced by the mouse surrogate Multabody in comparison to parental IgG and a species-mismatched malaria
PfCSP peptide fused to Helicobacter pylori ferritin (HpFerr). Mean values ± SD of n= 5 mice is shown in (b) and (d). Source data of panels b and d are
provided as a Source Data file.
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burying ~170 Å2 (24% of the total buried surface area on RBD)
and hence is central to the antibody–antigen interaction (Fig. S7a
and Table S3).
Detailed analysis of the RBD-52 Fab interface reveals that the
epitope of mAb 52 is shifted towards the core of the RBD
encompassing 20 residues of the RBM and seven residues in the
core domain (Fig. 5c, Fig. S7b, and Table S3). In agreement with
the competition data, antibody 52 and antibody 46 share a similar
binding site, although they approach the RBD with slightly
different angles (Fig. 5c, d and Fig. S7d). Inspection of previously
reported structures of RBD-antibody complexes reveal that
antibodies 46 and 52 target a site of vulnerability on the SARS-
CoV-2 spike that has not been described previously (Fig. 5e). The
epitope targeted by these antibodies is partially occluded by the
NTD in the S “closed” conformation, suggesting that the
mechanism of action for this class of antibodies could involve
Spike destabilization. Together, these data demonstrate that the
enhanced neutralization potency observed for the MB platform
through avidity is associated with mAbs that can target distinct
epitope bins on the RBD.
Multabodies overcome Spike sequence variability. To explore
whether MBs could potentially resist viral escape via their
enhanced binding avidity, we tested the effect of four naturally
occurring RBD mutations35 on the binding and neutralization of
the seven human mAbs of highest potency: L452R—located
within the epitope of antibodies 46 and 52 (bin 1), A475V and
V483A—located within the ACE2 binding site (bin 2), and the
circulating RBD variant N439K36 (Fig. 6a–c). In addition, the
impact of mutating Asn234—an N-linked glycosylation site—to
Gln was also assessed because the absence of glycosylation at this
site has been previously reported to decrease sensitivity to neu-
tralizing antibodies targeting the RBD35. The more infectious PsV
variant D614G37 was also included in the panel. As expected,
mutation L452R significantly decreased binding and potency of
mAbs 52 and 46, while antibody 298 was sensitive to mutation
A475V (Fig. 6b, c). Deletion of the N-linked glycan at position
Asn234 increased viral resistance to the majority of the anti-
bodies, especially mAbs 46, 80, and 324, emphasizing the
importance of glycans in viral antigenicity (Fig. 6c). Strikingly, the
following antibody specificities in the MB format were minimally
impacted in their exceptional neutralization potency by any S
mutation: 298, 80, 324, and 236 (Fig. 6d). Mutation L452R
decreased the sensitivity of the 46-MB and 52-MB but in contrast
to their parental IgGs, they remained neutralizing against this
PsV variant (Fig. 6d). The more infectious SARS-CoV-2 PsV
variant D614G was neutralized with similar potency as the WT
PsV for both IgGs and MBs (Fig. 6c and Fig. S8a).
MB cocktails consisting of three monospecific MBs resulted in
pan-neutralization across all PsV variants without a significant
loss in potency and hence achieved a 100–1000-fold higher
potency compared to the corresponding IgG cocktails (Fig. 6e and
Fig. 3 Protein engineering to multimerize IgG-like particles against SARS-CoV-2. a Schematic representation of the human apoferritin split design. b
Negative stain electron micrograph of the MB. (Scale bar 50 nm, representative of two independent experiments). c Hydrodynamic radius (Rh) of the MB.
d Avidity effect on the binding (apparent KD) of 4A8 (purple) and BD23 (gray) to the SARS-CoV-2 Spike. e Sensograms of BD23 IgG and MB with different
Fc sequence variants binding to FcγRI (top row), FcRn at endosomal pH (middle row) and FcRn at physiological pH (bottom row). Red lines represent raw
data whereas black lines represent global fits. f Neutralization of SARS-CoV-2 PsV by 4A8 and BD23 IgGs and MBs. Representative data of three
biologically independent samples. The mean values ± SD for two technical replicates is shown in each neutralization plot. Median IC50 values of the three
biologically independent replicates are indicated. Source data are provided as a Source Data file.
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Fig. S8c, d). In order to achieve breadth within a single molecule,
we next generated tri-specific MBs by combining multimerization
subunits displaying three different Fabs in the same MB assembly
(Fig. S8b). Notably, the resulting tri-specific MBs exhibited pan-
neutralization while preserving the exceptional neutralization
potency of the monospecific versions including against the
B.1.351 PsV variant (Fig. 6e, f and Fig. S8c, d). The highest
potency was observed for the 298-324-46 combination (Fig. S8c,
e), where the tri-specific MB achieved exceptional potency
beyond that observed for some of the most potent IgGs reported
to date and that we generated recombinantly from available
sequences (Fig. 6g). In addition, the MB format was able to
increase the potency of these previously reported highly potent
IgGs by a further one to two orders of magnitude against PsV and
live replicating SARS-CoV-2 virus (Fig. 6h), thus highlighting the
plug-and-play nature of the MB and the ability of multivalency to
enhance the neutralization capacity of mAbs across a range of
potencies.
Discussion
In this study, we reveal how binding avidity can be leveraged as
an effective mechanism to propel antibody neutralization potency
and resistance from viral mutations. To this effect, we used
protein engineering to develop a plug-and-play antibody-
multimerization platform that increases avidity of mAbs
targeting SARS-CoV-2. The seven most potent MBs have IC50
values of 0.2 to 2 ng/mL (9 × 10−14 to 9 × 10−13 M) against
SARS-CoV-2 PsVs and therefore are, to our knowledge, within
the most potent antibody-like molecules reported to date against
SARS-CoV-2.
The MB platform was designed to include key favorable
attributes from a developability perspective. First, the ability to
augment antibody potency is independent of antibody sequence,
format or epitope targeted. The modularity and flexibility of the
platform was exemplified by enhancing the potency of a VHH
and multiple Fabs that target non-overlapping regions on two
SARS-CoV-2 S sub-domains (RBD and NTD). Using the MB to
enhance the potency of VHH domains could provide particular
value to this class of molecules since its small size allows highly
efficient multimerization. Second, in contrast to other approaches
that enhance avidity through tandem fusions of single chain
variable fragments38,39, MBs do not suffer from low stability and
in fact self-assemble into highly stable particles with aggregation
temperatures similar to those of their parental IgGs. Third,
alternative multimerization strategies like streptavidin40, ver-
otoxin B subunit scaffolds41, or viral-like nanoparticles42 face
immunogenicity challenges and/or poor bioavailability because of
the absence of a Fc fragment and therefore the inability to
undergo FcRn–mediated recycling. The light chain of apoferritin
is fully human, biologically inactive, has been engineered to
Fig. 4 The Multabody enhances the potency of human mAbs from phage display. a Work flow for the identification of potent anti-SARS-CoV-2
neutralizers using the MB technology. Created with Biorender. b Comparison of neutralization potency between IgGs (cyan) and MBs (pink) that display
the same human Fab sequences derived from phage display. c IC50 values fold increase upon multimerization. d Apparent affinity (KD), association (kon),
and dissociation (koff) rates of the most potent neutralizing MBs (pink) compared to their IgG counterparts (cyan) for binding the SARS-CoV-2 S protein.
Three biological replicates and their mean are shown for IC50 values in (b) and (c). Source data of panels b–d are provided as a Source Data file.
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include Fc domains, and despite multimerization of >24 Fab/Fc
fragments, has a Rh similar to an IgM. As such, a surrogate
mouse MB did not elicit antidrug antibodies in mice and similar
to its parental IgG was detectable in the sera for over a week.
However, in vivo bioavailability of the MB was dependent on its
binding affinity to FcγRs, suggesting that Fc avidity will need to
be carefully fine-tuned for efficient translation of the MB to the
clinic. In addition, further studies will be needed to evaluate how
the MB distributes at anatomical sites of interest, such as the
lungs in the case of SARS-CoV-2 infection. The plug-and-play
nature of the Multabody also lends itself to exploring alternate
half-life extending moieties other than the Fc if bioavailability is
the only desired trait absent of effector functions e.g., human
serum albumin43, or binding moieties that bind human serum
albumin44,45.
Different increases in neutralization potency were observed for
different mAb sequences tested on the MB against SARS-CoV-2.
This suggests that the ability of the MB to enhance potency may
depend on epitope location on the Spike, or the geometry of how
the Fabs engage the antigen to achieve neutralization. The fact
that the neutralization of two out of 20 SARS-CoV-2 RBD bin-
ders were not rescued by the MB platform suggests limitations
based on mAb sequences and binding properties alone. Never-
theless, the capacity of the MB to transform avidity into neu-
tralization potency across a range of epitope specificities on the
SARS-CoV-2 Spike highlights the potential for using this
technology broadly. It will be interesting to explore the potency-
enhancement capacity of the MB platform against viruses with
low surface spike density like HIV-146, or against other targets
like the tumor necrosis factor receptor superfamily, where biva-
lency of conventional antibodies limits their efficient activation47.
Virus escape can arise in response to selective pressure from
treatments or during natural selection. A conventional approach
to combat escape mutants is the use of antibody cocktails tar-
geting different epitopes. MBs showed a lower susceptibility to S
mutations in comparison to their parental IgGs, presumably
because the loss in affinity was compensated by enhanced binding
avidity. Hence, when used in cocktails, the MB overcame viral
sequence variability with exceptional potency. In addition, the
split MB design allows combination of multiple antibody speci-
ficities within a single multimerized molecule resulting in similar
potency and breadth as the MB cocktails. Importantly, the
B.1.351 variant of concern that can escape the neutralization of
several mAbs21–23 is neutralized with high potency by a tri-
specific Multabody, thus further highlighting the capacity of these
molecules to resist viral escape. Multi-specificity within the same
particle could offer additional advantages such as intra-S avidity
and synergy for the right combination of mAbs, setting the stage
for further investigation of different combinations of mAb spe-
cificities on the MB. Avidity and multi-specificity could also be
leveraged to deliver a single molecule that neutralizes potently
across viral genera, such as betacoronaviruses.
Fig. 5 Epitope delineation of the most potent mAb specificities. a Surface and cartoon representation of RBD (light green for the core and dark green for
RBM) and ACE266 (light brown) binding. Heat map showing binding competition experiments. High signal responses (red) represent low competition
while low signal responses (white) correspond to high competition. Epitope bins are highlighted by dashed-line boxes. b 15.0 Å filtered cryo-EM
reconstruction of the Spike (gray) in complex with Fab 80 (yellow), 298 (orange), and 324 (red). The RBD and NTD are shown in green and blue,
respectively. c Cryo-EM reconstruction of the Fab 46 (pink) and RBD (green) complex. A RBD66 secondary structure cartoon is fitted into the partial
density observed for the RBD. d Crystal structure of the ternary complex formed by Fab 52 (purple), Fab 298 (orange), and RBD (green). e Composite
image depicting the side and top view of the unliganded (PDB 6XM4) and the antibody-bound SARS-CoV-2 spike with available PDB or EMD
entries3,4,9,10,13,15,17,67–72. Inset: close up view of antibodies targeting different antigenic sites on the RBD. The mAb with the lowest reported IC50 value
against SARS-CoV-2 PsV was selected as a representative antibody of the bin (highlighted in bold) and those antibodies with similar binding epitopes
are listed in the same color below (color coding of Spike, NTD and RBD as in (b)). Individual protomers in the unliganded spike are shown in white, pink,
and purple.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23825-2 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:3661 | https://doi.org/10.1038/s41467-021-23825-2 | www.nature.com/naturecommunications 7
Overall, the MB platform provides a tool to surpass antibody
affinity limits and generate broad and potent neutralizing mole-
cules while by-passing extensive antibody discovery or engi-
neering efforts. This platform is an example of how binding
avidity can be leveraged to accelerate the timeline to discovery of
the most potent biologics against infectious diseases of global
health importance.
Methods
Protein expression and purification. Genes encoding VHH-human apoferritin
fusion, Fc fusions, Fabs, IgG, and RBD mutants were synthesized and cloned by
GeneArt (Life Technologies) into the pcDNA3.4 expression vector. All constructs
were expressed transiently in HEK 293F cells (Thermo Fisher Scientific) at a
density of 0.8 × 106 cells/mL with 50 μg of DNA per 200 mL of cells using Fecto-
PRO (Polyplus Transfections) in a 1:1 ratio unless specified otherwise. After
6–7 days of incubation at 125 rpm oscillation at 37 °C, 8% CO2, and 70% humidity
in a Multitron Pro shaker (Infors HT), cell suspensions were harvested by cen-
trifugation at 5000 × g for 15 min and supernatants were filtered through a 0.22 μm
Steritop filter (EMD Millipore). Fabs and IgGs were transiently expressed by co-
transfecting 90 μg of the LC and the HC in a 1:2 ratio and purified using
KappaSelect affinity column (GE Healthcare) and HiTrap Protein A HP column
(GE Healthcare), respectively with 100 mM glycine pH 2.2 as the elution buffer.
Eluted fractions were immediately neutralized with 1M Tris-HCl, pH 9.0, and
further purified using a Superdex 200 Increase size exclusion column (GE
Healthcare). Fc fusions of ACE2 and VHH-72 were purified the same way as IgGs.
The VHH-72 apoferritin fusion was purified by hydrophobic interaction chro-
matography using a HiTrap Phenyl HP column and the eluted fraction was loaded
onto a Superose 6 10/300 GL size exclusion column (GE Heathcare) in 20 mM
sodium phosphate pH 8.0, 150 mM NaCl. Wild type (BEI NR52309) and mutant
RBDs, the prefusion S ectodomain (BEI NR52394) and Fc receptors (FcRn and
FcγRI) from mouse and human were purified using a HisTrap Ni-NTA column
(GE Healthcare). Ni-NTA purification was followed by Superose 6 in the case of
the S trimer and Superdex 200 Increase size exclusion columns (GE Heathcare) in
the case of the RBD and Fc receptors, in all cases in 20 mM phosphate pH 8.0, 150
mM NaCl buffer.
Design, expression, and purification of Multabodies. All molecules referred
herein as Multabodies contain scFab and scFc fragments. The scFabs and scFc
polypeptide constructs were generated using a 70 amino acid flexible linker
[(GGGGS)x14] to generate heterodimers and homodimer fragments, respectively.
Specifically, the C terminus of the Fab light chain is fused, through the linker, to the
Fig. 6 Multabodies overcome SARS-CoV-2 sequence diversity. a Cartoon representation of the RBD showing four naturally occurring mutations as
spheres. The epitopes of mAbs 52 (light pink) and 298 (yellow) are shown as representative epitopes of each bin. b Affinity and c IC50 fold-change
comparison between WT and mutated RBD and PsV, respectively. d Neutralization potency of IgG (gray bars) vs MB (dark red bars) against SARS-CoV-2
PsV variants in comparison to WT PsV. e Neutralization potency comparison of two IgG cocktails (three IgGs), monospecific MB cocktails (three MBs) and
tri-specific MBs against WT SARS-CoV-2 PsV and variants. mAbs sensitive to one or more PsV variants (d) were selected to generate the cocktails and
the tri-specific MBs. f Neutralization potency of the tri-specific 298-80-52 MB against SARS-CoV-2 B.1.351 PsV variant. g IC50 values in PsV (y-axis) and
replication competent SARS-CoV-2 virus (SB2-P4-PB: x-axis) demonstrating the ability of tri-specific MBs (red) to enhance potency across a wide range of
mAb characteristics (blue and black). h IC50 values fold increase upon multimerization. The mean of three biological replicates is shown in (b–h). Source
data of panels d–h are provided as a Source Data file.
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N terminus of the Fab heavy chain. In the case of the scFc, the two single Fc chains
that form the functional homodimer Fc were fused in tandem. The individual
domains are fused to apoferritin monomers with a 25 amino acid linker:
(GGGGS)x5. Genes encoding scFab and scFc fragments linked to half apoferritin
were generated by deletion of residues 1 to 90 (C-Ferritin) and 91 to 175 (N-
Ferritin) of the light chain of human apoferritin. Transient transfection of the
Multabodies in HEK 293F cells were obtained by mixing 66 μg of the plasmids
scFab-human apoferritin: scFc-human N-Ferritin: scFab-C-Ferritin in a 2:1:1 ratio.
Addition of scFab-human apoferritin allowed efficient Multabody assembly and
increased the number of Fab’s compared to Fc’s in the final molecule, thus favoring
Fab avidity over Fc avidity. In the case of multi-specific Multabodies, a 4:2:1:1 ratio
of scFab1-human apoferritin: scFc-human N-Ferritin: scFab2-C-Ferritin: scFab3-
C-Ferritin was used. The DNA mixture was filtered and incubated at room tem-
perature (RT) with 66 μl of FectoPRO before adding to the cell culture. Split
Multabodies were purified by affinity chromatography using a HiTrap Protein A
HP column (GE Healthcare) with 20 mM Tris pH 8.0, 3 M MgCl2 and 10% glycerol
elution buffer. Fractions containing the protein were concentrated and further
purified by gel filtration on a Superose 6 10/300 GL column (GE Healthcare).
Negative-stain electron microscopy. Three microliters of Multabody at a con-
centration approximately of 0.02 mg/mL was placed on the surface of a carbon-
coated copper grid that had previously been glow-discharged in air for 15 s, allowed
to adsorb for 30 s, and stained with 3 μL of 2% uranyl formate. Excess stain was
removed immediately from the grid using Whatman No. 1 filter paper and an
additional 3 μL of 2% uranyl formate was added for 20 s. Grids were imaged with a
FEI Tecnai T20 electron microscope operating at 200 kV and equipped with an
Orius charge-coupled device (CCD) camera (Gatan Inc).
Biolayer interferometry. Direct binding kinetics measurements were conducted
using an Octet RED96 BLI system (Sartorius ForteBio) in PBS pH 7.4, 0.01% BSA,
and 0.002% Tween at 25 °C. His-tagged RBD, SARS-CoV-2 Spike was loaded onto
Ni-NTA (NTA) biosensors (Sartorius ForteBio) to reach a BLI signal response of
0.8 nm. Association rates were measured by transferring the loaded biosensors to
wells containing a two-fold dilution series from 250 to 8 nM (Fabs), 125 to 4 nM
(IgG), and 16 to 0.5 nM (MB). Dissociation rates were measured by dipping the
biosensors into buffer-containing wells. The duration of each step was 180 s. Fc
characterization in the split Multabody design was assessed by measuring binding
to hFcγRI and hFcRn loaded onto Ni-NTA (NTA) biosensors following the
experimental conditions and concentration ranges indicated above. To probe the
theoretical capacity of the Multabodies to undergo endosomal recycling, binding to
the hFcRn β2-microglobulin complex was measured at physiological (7.4) and
endosomal (5.6) pH. Similarly, Fc characterization of the mouse surrogate MB was
assessed by measuring binding to mFcγRI and mFcRn, pre-immobilized onto Ni-
NTA (NTA) biosensors. Two-fold dilution series from 100 to 3 nM (IgG) and 10 to
0.3 nM (MB) were used. Analysis of the sensograms was performed using the Octet
software, with a 1:1 fit model. Competition assays were performed in a two-step
binding process. Ni-NTA biosensors preloaded with His-tagged RBD were first
dipped into wells containing the primary antibody at 50 μg/mL for 180 s. After a 30
s baseline period, the sensors were dipped into wells containing the second anti-
body at 50 μg/ml for an additional 300 s. All incubation steps were performed in
PBS pH 7.4, 0.01% BSA, and 0.002% Tween at 25 °C. ACE2-Fc was used to map
mAb binding to the receptor binding site.
Dynamic light scattering. The Rh of the Multabody was determined by dynamic
light scattering (DLS) using a DynaPro Plate Reader III (Wyatt Technology). About
20 μL of the Multabody at a concentration of 1 mg/mL was added to a 384-well
black, clear bottom plate (Corning) and measured at a fixed temperature of 25 °C
with a duration of 5 s per read. Particle size determination and polydispersity were
obtained from the accumulation of five reads using the Dynamics software (Wyatt
Technology).
Aggregation temperature. Aggregation temperature (Tagg) of the Multabodies
and parental IgGs were determined using a UNit instrument (Unchained Labs).
Samples were concentrated to 1.0 mg/mL and subjected to a thermal ramp from 25
to 95 °C with 1 °C increments. Tagg was determined as the temperature at which
50% increase in the static light scattering at a 266 nm wavelength relative to
baseline was observed (i.e., the maximum value of the differential curve). The
average and the standard error of two independent measurements were calculated
using the UNit analysis software.
Pharmacokinetics and immunogenicity. A surrogate Multabody composed of the
scFab and scFc fragments of mouse HD37 (anti-hCD19) IgG2a fused to the N-
terminus of the light chain of mouse apoferritin (mFerritin) was used for the study.
HD37 scFab-mFerritin: Fc-mFerritin: mFerritin in a 2:1:1 ratio was transfected and
purified following the procedure described above. L234A, L235A, and P329G
(LALAP) mutations were introduced in the mouse IgG2a Fc-construct to silence
effector functions of the Multabody48. In vivo studies were performed using 12-
week-old male C57BL/6 mice purchased from Charles River (Strain code: 027),
housed in individually-vented cages under 12 h light/dark cycle (7 a.m./7 p.m.) at a
temperature of 21–23 °C and a humidity of 40–55%. All procedures were approved
by the Local Animal Care Committee at the University of Toronto Scarborough. A
single injection of ~5 mg/kg of Multabodies or control samples (HD37 single chain
IgG-IgG1 or IgG2a subtypes) and Helicobacter pylori ferritin (HpFerritin)-PfCSP
malaria peptide in 200 μL of PBS (pH 7.5) were subcutaneously injected. Blood
samples were collected at multiple time points and serum samples were assessed for
levels of circulating antibodies and anti-drug antibodies by ELISA. Briefly, 96-well
Pierce Nickel Coated Plates (Thermo Fisher) were coated with 50 μL at 0.5 μg/ml of
the His6x-tagged antigen hCD19 to determine circulating HD37-specific con-
centrations using reagent-specific standard curves for IgGs and Multabodies. HRP-
ProteinA (Invitrogen) was used to detect the levels of IgG/MBs bound (dilution
1:10,000). For anti-drug-antibody determination, Nunc MaxiSorp plates (Biole-
gend) were coated with a 12-mer HD37 scFab-mFerritin or with the HpFerritin-
PfCSP malaria peptide. 1:100 sera dilution was incubated for 1 h at RT and further
develop using HRP-ProteinA (Invitrogen) as a secondary molecule (dilution
1:10,000). The chemiluminescence signal at 450 nm was quantified using a Synergy
Neo2 Multi-Mode Assay Microplate Reader (Biotek Instruments).
Biodistribution. Eight-week-old male BALB/c mice were purchased from The
Jackson Laboratory and housed in individually-vented caging. Mice were housed
14 h of light/10 h dark with phased in dawn to dusk intensity, maximum at noon at
a temperature of 20–21 °C and a humidity of 40–60%. All procedures were
approved by the Local Animal Care Committee at the University of Toronto.
Multabodies composed of the scFab and scFc fragments of mouse HD37 IgG2a
fused to the N-terminus of mouse apoferritin light chain was used for this study.
HD37 IgG2a Multabody or control samples (HD37 single chain IgG2a) were
fluorescently conjugated with Alexa-647 using Alexa FluorTM 647 Antibody
Labeling kit (Invitrogen) as per the manufacturer’s instruction. The 15 nm gold
nanoparticles labeled with Alexa FluorTM 647 were purchased from Creative
Diagnostics (GFLV-15). PerkinElmer IVIS Spectrum (PerkinElmer) was used to
conduct noninvasive biodistribution experiments. BALB/c mice were injected
subcutaneously into the loose skin over the shoulders with ~5 mg/kg of the MB,
HD37 IgG2a, or gold nanoparticles in 200 μL of PBS (pH 7.5) and imaged at time
0, 1 h, 6 h, 24 h, 2, 3, 4, 8, and 11 days following injection. Prior to imaging, mice
were placed in an anesthesia induction chamber containing a mixture of isoflurane
and oxygen for 1 min. Anesthetized mice were then placed in the prone position at
the center of a built-in heated docking system within the IVIS imaging system
(maintained at 37 °C and supplied with a mixture of isoflurane and oxygen). For
whole body 2D imaging, mice were imaged for 1–2 s (excitation 640 nm and
emission 680 nm) inside the imaging system. Data were analyzed using the IVIS
software (Living Image Software for IVIS). After confirming the fluorescent signal
from 2D epi-illumination images, 3D transilluminating fluorescence imaging
tomography (FLIT) was performed on regions of interest using a built-in scan field
of 3 × 3 or 3 × 4 transillumination positions. A series of 2D fluorescent surface
radiance images were taken at various transillumination positions using an exci-
tation of 640 and 680 nm emission. A series of CT scans were also taken at the
corresponding positions. A 3D distribution map of the fluorescent signal was
reconstructed by combining fluorescent signal and CT scans. Resulting 3D fluor-
escent images were thresholded based on the 3D images of PBS injected mice taken
at the corresponding body positions. Images were mapped to the rainbow LUT in
the IVIS software, with the upper end of the color scale set to 50 pmol M−1 cm−1
for mice injected with gold nanoparticles, and 1 000 pmol M−1 cm−1 for MB and
IgG2a injected mice, to allow for better visualization of biodistribution over the
time course. A mouse organ registration feature of the IVIS software was used as a
general guideline for assessing the sample body locations from 3D images.
Panning of phage libraries against the RBD of SARS-CoV-2. The commercial
SuperHuman 2.0 Phage library (Distributed Bio/Charles River Laboratories) was
used to identify monoclonal antibody binders to the SARS-CoV-2 RBD. For this
purpose, an RBD-Fc-Avi tag construct of the SARS-CoV-2 was expressed in the
EXPi-293 mammalian expression system. This protein was subsequently purified
by protein G Dynabeads, biotinylated and quality-controlled for biotinylation and
binding to ACE2 recombinant protein (Sino Biologics Inc). The SuperHuman 2.0
Phage library (5 × 1012) was heated for 10 min at 72 °C and de-selected against
Protein G DynabeadsTM (Invitrogen), M-280 Streptavidin DynabeadsTM (Invi-
trogen), Histone from Calf Thymus (Sigma), Human IgG (Sigma) and ssDNA-
Biotin NNK from Integrated DNA Technologies and DNA-Biotin NNK from
Integrated DNA Technologies. Next, the library was panned against the RBD-
captured by M-280 Streptavidin DynabeadsTM using an automated protocol on
Kingfisher FLEX (Thermofisher). Selected phages were acid eluted from the beads
and neutralized using Tris-HCl pH 7.9 (Teknova). ER2738 cells were infected with
the neutralized phage pools at OD600= 0.5 at a 1:10 ratio and after 40 min incu-
bation at 37 °C and 100 rpm, the phage pools were centrifuged and incubated on
agar with antibiotic selection overnight at 30 °C. The rescued phages were pre-
cipitated by PEG and subjected to three additional rounds of soluble-phase auto-
mated panning. PBST/1% BSA buffer and/or PBS/1% BSA was used in the de-
selection, washes and selection rounds.
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Screening of anti-SARS-CoV-2 scFvs in bacterial PPE with SARS-CoV-2 RBD.
Anti-SARS-CoV-2 RBD scFvs selected from phage display were expressed and
screened using high-throughput surface plasmon resonance (SPR) on Carterra LSA
Array SPR instrument (Carterra) equipped with HC200M sensor chip (Carterra) at
25 °C. A V5 epitope tag was added to the scFv to enable capture via immobilized
anti-V5 antibody (Abcam, Cambridge, MA) that was pre-immobilized on the chip
surface by standard amine-coupling. Briefly: the chip surface was first activated by
10 min injection of a 1:1:1 (v/v/v) mixture of 0.4 M 1-ethyl-3-(3-dimethylamino-
propyl) carbodiimide hydrochloride (EDC), 0.1 M N-hydroxysulfosuccinimide
(sNHS) and 0.1 M 2-(N-morpholino) ethanesulfonic acid (MES) pH 5.5. Then, 50
μg/ml of anti-V5 tag antibody prepared in 10 mM sodium acetate pH 4.3 was
coupled for 14 min and the excess reactive esters were blocked with 1M ethano-
lamine HCl pH 8.5 during a 10 min injection. For screening, a 384-ligand array
comprising of crude bacterial periplasmic extracts (PPE) containing the scFvs (one
spot per scFv) was prepared. Each extract was prepared at a twofold dilution in
running buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.01% (v/
v) Tween-20 (HBSTE)) and printed on the anti-V5 surface for 15 min. SARS-CoV-
2 RBD Avi Tev His tagged was then prepared at 0, 3.7, 11.1, 33.3, 100, 37, and 300
nM in 10 mM HEPES pH 7.4, 150 mM NaCl, and 0.01% (v/v) Tween-20 (HBST)
supplemented with 0.5 mg/ml BSA and injected as analyte for 5 min with a 15 min
dissociation time. Samples were injected in ascending concentration without any
regeneration step. Binding data from the local reference spots was used to sub-
tracted signal from the active spots and the nearest buffer blank analyte responses
were subtracted to double-reference the data. The double-referenced data were
fitted to a simple 1:1 Langmuir binding model in Carterra’s Kinetic Inspection Tool
(version Oct. 2019). Twenty medium-affinity binders from phage display screening
were selected for the present study.
Pseudovirus production and neutralization. SARS-CoV-2 pseudotyped viruses
(PsV) were generated using an HIV-based lentiviral system49 with few modifica-
tions. Briefly, 293T cells were co-transfected with a lentiviral backbone encoding
the luciferase reporter gene (BEI NR52516), a plasmid expressing the Spike (BEI
NR52310) and plasmids encoding the HIV structural and regulatory proteins Tat
(BEI NR52518), Gag-pol (BEI NR52517), and Rev (BEI NR52519) using BioT
transfection reagent (Bioland Scientific) and following the manufacturer’s
instructions. 24 h post transfection at 37 °C, 5 mM sodium butyrate was added to
the media and the cells were incubated for an additional 24–30 h at 30 °C. SARS-
CoV-2 Spike mutant D614G was kindly provided by D.R. Burton (The Scripps
Research Institute), SARS-COV-2 PsV variant B.1.351 was kindly provided by D.D.
Ho (Columbia University) and the rest of the PsV mutants were generated using
the KOD-Plus mutagenesis kit (Toyobo, Osaka, Japan) using primers described in
Table S4. PsV particles were harvested, passed through 0.45 μm pore sterile filters
and finally concentrated using a 100 K Amicon (Merck Millipore Amicon-Ultra 2.0
Centrifugal Filter Units).
Neutralization was determined in a single-cycle neutralization assay using
293T-ACE2 cells (BEI NR52511) and HeLa-ACE2 cells (kindly provided by D.R.
Burton; The Scripps Research Institute). Cells were seeded the day before the
experiment at a density of 10,000 cells/well in a 100 μl volume. In the case of
293T cells, plates where pre-coated with poly-L-lysine (Sigma-Aldrich). The day of
the experiment, 50 μl of serially diluted IgGs and MB samples were incubated with
50 μl of PsV for 1 h at 37 °C. After 1 h incubation, the incubated volume was added
to the cells and incubated for 48 h. PsV neutralization was monitored by adding 50
μl Britelite plus reagent (PerkinElmer) to 50 μl of the cells and after 2 min
incubation, the volume was transferred to a 96-well white plate (Sigma-Aldrich)
and the luminescence in relative light units (RLUs) was measured using a Synergy
Neo2 Multi-Mode Assay Microplate Reader (Biotek Instruments). Two to three
biological replicates with two technical replicates each were performed. IC50 fold
increase was calculated as:
IgG IC50ðμg=mLÞ=MB IC50ðμg=mLÞ
Authentic virus neutralization. VeroE6 cells were seeded in a 96 F plate at a
concentration of 30,000/well in DMEM supplemented with 100 U Penicillin, 100 U
Streptomycin, and 10% FBS. Cells were allowed to adhere to the plate and rest
overnight. After 24 h, fivefold serial dilutions of the IgG and MB samples were
prepared in DMEM supplemented with 100 U Penicillin and 100 U Streptomycin
in a 96 R plate in quadruplicates (25 µL/well). About 25 µL of SARS-CoV-2/SB2-
P4-PB50 Clone 1 was added to each well at 100TCID/well and incubated for 1 h at
37 °C with shaking every 15 min. After co-culturing, the media from the VeroE6
plate was removed, and 50 µL antibody-virus sample was used to inoculate VeroE6
cells in quadruplicates for 1 h at 37 °C, 5% CO2, shaking every 15 min. After 1 h
inoculation, the inoculum was removed and 200 µL of fresh DMEM supplemented
with 100U Penicillin, 100U Streptomycin, and 2% FBS was added to each well. The
plates were further incubated for 5 days. The cytopathic effect (CPE) was mon-
itored and PRISM was used to calculate IC50 values. Three biological replicates with
four technical replicates each were performed.
Cross-linking of Spike protein with Fabs 80, 298, and 324. About 100 µg of
Spike trimer was mixed with 2x molar excess of Fab 80, 298, or 324 in 20 mM
HEPES pH 7.0 and 150 mM NaCl. Proteins were crosslinked by addition of 0.075%
(v/v) glutaraldehyde (Sigma Aldrich) and incubated at RT for 120 min. Complexes
were purified via size exclusion chromatography (Superose6 Increase 10/300 GL,
GE Healthcare), concentrated to 0.5 mg/mL and directly used for cryo-EM grid
preparation.
Cross-linking of Fab 46-RBD complex. About 100 µg of Fab 46 was mixed with
2x molar excess of RBD in 20 mM HEPES pH 7.0 and 150 mM NaCl. The complex
was crosslinked by addition of 0.05% (v/v) glutaraldehyde (Sigma Aldrich) and
incubated at RT for 45 min. The cross-linked complex was purified via size
exclusion chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare),
concentrated to 2.0 mg/ml and directly used for cryo-EM grid preparation.
Cryo-EM data collection and image processing. Three microliters of sample was
deposited on holey gold grids prepared in-house51, which were glow-discharged in
air for 15 s with a PELCO easiGlow (Ted Pella) before use. Sample was blotted for
6 s with a modified FEI Mark III Vitrobot (maintained at 4 °C and 100% humidity)
using an offset of −5, and subsequently plunge-frozen in a mixture of liquid ethane
and propane. Data were acquired at 300 kV with a Thermo Fisher Scientific Titan
Krios G3 electron microscope and prototype Falcon 4 camera operating in electron
counting mode at 250 frames/s. Movies were collected for 9.6 s with 29 exposure
fractions, a camera exposure rate of ~5 e−/pix/s, and total specimen exposure of
~44 e−/Å2. No objective aperture was used. The pixel size was calibrated at 1.03 Å/
pixel from a gold diffraction standard. The microscope was automated with the
EPU software package and data collection were monitored with cryoSPARC Live52.
To overcome preferred orientation encountered with some of the samples, tilted
data collection was employed53. For the Spike-Fab 80 complex, 820 0˚ tilted movies
and 2790 40˚ tilted movies were collected. For the Spike-Fab 298 complex, 4259 0˚
tilted movies and 3513 40˚ tilted movies were collected. For the Spike-Fab 324
complex, 1098 0˚ tilted movies and 3380 40˚ tilted movies were collected. For the
RBD-Fab 46 complex, 4722 0˚ tilted movies were collected. For 0˚ tilted movies,
cryoSPARC patch motion correction was performed. For 40˚ tilted movies, Relion
MotionCorr54,55 was used. Micrographs were then imported into cryoSPARC and
patch CTF estimation was performed. Templates generated from 2D classification
during the cryoSPARC Live session were used for template selection of particles.
2D classification was used to remove junk particle images, resulting in a dataset of
80,951 particle images for the Spike-Fab 80 complex, 203,138 particle images for
the Spike-Fab 298 complex, 64,365 particle images for the Spike-Fab 324 complex,
and 2,143,629 particle images for the RBD-Fab 46 complex. Multiple rounds of
multi-class ab initio refinement were used to clean up the particle image stacks, and
homogeneous refinement was used to obtain consensus structures. For tilted
particles, particle polishing was done within Relion at this stage and reimported
back into cryoSPARC. For the Spike-Fab complexes, extensive flexibility was
observed. 3D variability analysis was performed56 and together with heterogeneous
refinement used to classify out the different states present. Nonuniform refinement
was then performed on the final set of particle images57. For the RBD-Fab 46
complex, cryoSPARC ab initio refinement with three classes was used iteratively to
clean up the particle image stack. Thereafter, the particle image stack with refined
Euler angles was brought into cisTEM for reconstruction58 to produce a 4.0 Å
resolution map. Transfer of data between Relion and cryoSPARC was done with
pyem59.
Crystallization and structure determination. A ternary complex of 52 Fab-298
Fab-RBD was obtained by mixing 200 µg of RBD with 2x molar excess of each Fab
in 20 mM Tris pH 8.0, 150 mM NaCl, and subsequently purified via size exclusion
chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare). Fractions
containing the complex were concentrated to 7.3 mg/ml and mixed in a 1:1 ratio
with 20% (w/v) 2-propanol, 20% (w/v) PEG 4000, and 0.1 M sodium citrate pH 5.6.
Crystals appeared after ~1 day and were cryoprotected in 10% (v/v) ethylene glycol
before being flash-frozen in liquid nitrogen.
Data were collected on the 23-ID-D beamline at the Argonne National
Laboratory Advanced Photon Source. The dataset was processed using XDS60 and
XPREP. Phases were determined by molecular replacement using Phaser61 with
CNTO88 Fab as a model for 52 Fab (PDB ID: 4DN3), 20358 Fab as a model for 298
Fab (PDB ID: 5CZX), and PDB ID: 6XDG as a search model for the RBD.
Refinement of the structure was performed using phenix.refine62 and iterations of
manual building in Coot63. PyMOL was utilized for structure analysis and figure
rendering64. Access to all software was supported through SBGrid65.
Representative electron density for the two Fab-RBD interfaces is shown in Fig.
S7e, f.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The electron microscopy maps have been deposited in the Electron Microscopy Data
Bank (EMDB) with accession codes EMD-22738, EMD-22739, EMD-22740, and EMD-
22741 (Table S1- https://doi.org/10.1101/2020.10.15.341636). The crystal structure of
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the 298-52-RBD complex (Table S2- https://doi.org/10.2210/pdb7K9Z/pdb) is available
from the Protein Data Bank under accession PDB ID: 7K9Z. The sequences of the
monoclonal antibodies used are provided with this paper (Supplementary Data 1).
Additional PDB/EMDB entries were used throughout the manuscript to perform a
comparative analysis of the different epitope bins targeted by mAbs. The entries used in
this analysis are: REGN10933 (PDB ID: 6XDG), CV30 (PDB ID: 6XE1), C105 (PDB ID:
6XCM), COVA2-04 (PDB ID: 7JMO), COVA2-39 (PDB ID: 7JMP), CC12.1 (PDB ID:
6XC2), BD23 (PDB ID: 7BYR), B38 (PDB ID: 7BZ5), P2C-1F11 (PDB ID: 7BWJ), 2-4
(PDB ID: 6XEY), CB6 (PDB ID: 7C01), REGN10987 (PDB ID: 6XDG), S309 (PDB ID:
6WPS, 6WPT), EY6A (PDB ID: 6ZCZ), CR3022 (PDB ID: 6YLA), H014 (PDB ID:
7CAH), 4-8 (EMDB ID: 22159), 4A8 (PDB ID: 7C2L), and 2-43 (EMDB ID: 22275). All
data supporting the findings of this study are available within the paper and its
supplementary information files. Requests for material can be directed to Jean-Philippe
Julien (jean-philippe.julien@sickkids.ca). All materials and reagents will be available
upon establishing a material transfer agreement (MTA). Source data are provided with
this paper.
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